A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
ADMA BIOLOGICS, INC.
ADMA
$2.0B
Mkt Cap
$8.27
-1.19%
ADMA BIOLOGICS, INC. (ADMA) has a current P/E ratio of 13.8, compared to its historical median P/E of 26.8. The stock is currently considered Cheap based on its historical valuation range.
ADMA BIOLOGICS, INC. (ADMA) has a 5-year average return on invested capital (ROIC) of 7.0%. This is below average and may indicate limited pricing power.
ADMA BIOLOGICS, INC. (ADMA) has a market capitalization of $1.9B. It is classified as a small-cap stock.
ADMA BIOLOGICS, INC. (ADMA) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 1.66%.
Based on historical P/E analysis, ADMA BIOLOGICS, INC. (ADMA) appears cheap. The current P/E of 13.8 is 49% below its historical median of 26.8. The estimated fair value CAGR (P/E method) is 89.5%.
ADMA BIOLOGICS, INC. (ADMA) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
ADMA BIOLOGICS, INC. (ADMA) reported annual revenue of $510 million in its most recent fiscal year, based on SEC EDGAR filings.
Unless the context otherwise requires, references in this Business section to “ADMA,” “ADMA Biologics,” the “Company,” “we,” “us” and “our” refer to ADMA Biologics, Inc., a Delaware corporation, as well as its wholly owned subsidiaries, ADMA BioManufacturing, LLC, a Delaware limited liability company (“ADMA BioManufacturing”), ADMA BioCenters Georgia Inc., a Delaware corporation (“ADMA BioCenters”) and ADMA Plasma Biologics, Inc., a Delaware corporation (“ADMA Plasma Biologics”). We are a U.S. based end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Our targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 510M | 510M | 426M | 258M | 154M | 81M |
| Net Income | 165M | 147M | 198M | -28M | -66M | -72M |
| EPS | $0.70 | $0.60 | $0.81 | $-0.13 | $-0.33 | $-0.51 |
| Free Cash Flow | 108M | 28M | 110M | 4.0M | -73M | -126M |
| ROIC | 38.3% | 39.1% | 51.2% | 10.0% | -24.8% | -40.7% |
| Gross Margin | 61.3% | 57.4% | 51.5% | 34.4% | 22.9% | 1.4% |
| Debt/Equity | 0.50 | 0.17 | 0.24 | 1.05 | 1.02 | 0.73 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 215M | 191M | 139M | 22M | -39M | -58M |
| Operating Margin | 42.1% | 37.5% | 32.6% | 8.4% | -25.5% | -72.1% |
| ROE | 42.4% | 35.6% | 81.6% | -19.7% | -45.0% | -62.5% |
| Shares Outstanding | 232M | 245M | 244M | 217M | 200M | 140M |
| Metric | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | N/A | N/A | 11M | 23M | N/A | 29M | 42M | 81M | 154M | 258M | 426M | 510M | 510M |
| Gross Margin | N/A | N/A | 40.3% | -28.1% | N/A | -34.6% | -45.2% | 1.4% | 22.9% | 34.4% | 51.5% | 57.4% | 61.3% |
| R&D | 9.5M | 7.0M | 7.7M | 5.6M | 3.9M | 2.3M | 5.9M | 3.6M | 3.6M | 3.3M | 1.8M | 4.8M | 6.5M |
| SG&A | 4.8M | 6.7M | 8.5M | 19M | 23M | 26M | 35M | 43M | 52M | 59M | 74M | 92M | 94M |
| EBIT | -16M | -16M | -17M | -39M | -60M | -41M | -65M | -58M | -39M | 22M | 139M | 191M | 215M |
| Op. Margin | N/A | N/A | -162.6% | -172.7% | N/A | -141.1% | -153.8% | -72.1% | -25.5% | 8.4% | 32.6% | 37.5% | 42.1% |
| Net Income | -17M | -18M | -20M | -44M | -66M | -48M | -76M | -72M | -66M | -28M | 198M | 147M | 165M |
| Net Margin | N/A | N/A | -183.1% | -192.3% | N/A | -164.5% | -179.4% | -88.5% | -42.8% | -10.9% | 46.4% | 28.8% | 32.4% |
| Non-Recurring | 0 | 0 | 0 | 835K | -122K | 6.7M | -82K | -221K | -427K | -182K | -106K | -9K | -9K |
| Returns on Capital | |||||||||||||
| ROIC | -71.5% | -100.8% | -57.8% | -28.7% | -53.6% | -198.2% | -70.6% | -40.7% | -24.8% | 10.0% | 51.2% | 39.1% | 38.3% |
| ROE | -121.9% | -2188.9% | N/A | -243.9% | -218.8% | -210.1% | -132.4% | -62.5% | -45.0% | -19.7% | 81.6% | 35.6% | 42.4% |
| ROA | -57.0% | -70.8% | -82.3% | -66.5% | -66.8% | -44.7% | -45.3% | -29.6% | -21.1% | -8.3% | 48.3% | 26.4% | 24.9% |
| Cash Flow | |||||||||||||
| Op. Cash Flow | -15M | -15M | -18M | -37M | -63M | -76M | -102M | -112M | -60M | 8.8M | 119M | 50M | 128M |
| Free Cash Flow | -17M | -15M | -18M | -40M | -65M | -80M | -115M | -126M | -73M | 4.0M | 110M | 28M | 108M |
| Owner Earnings | -16M | -18M | -20M | -40M | -68M | -81M | -108M | -121M | -71M | -5.0M | 97M | 22M | 99M |
| CapEx | 2.3M | 26K | 73K | 2.7M | 2.1M | 3.8M | 13M | 14M | 14M | 4.8M | 8.2M | 23M | 20M |
| Maint. CapEx | 248K | 470K | 400K | 1.5M | 2.6M | 2.4M | 3.2M | 4.8M | 6.4M | 7.6M | 7.7M | 8.0M | 7.9M |
| Growth CapEx | 2.1M | 0 | 0 | 1.2M | 0 | 1.4M | 9.5M | 8.7M | 7.5M | 0 | 526K | 15M | 13M |
| D&A | 248K | 470K | 400K | 1.5M | 2.6M | 2.4M | 3.2M | 4.8M | 6.4M | 7.6M | 7.7M | 8.0M | 7.9M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 54.2% | 6.9% | 44.8% | 15.9% |
| Capital Allocation | |||||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 477K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 32M | 32M |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.7% | 1.7% |
| Stock-Based Comp | 1.2M | 1.7M | 1.3M | 1.6M | 2.2M | 2.7M | 2.9M | 3.5M | 5.2M | 6.2M | 14M | 20M | 22M |
| Debt Repayment | 13K | 14K | 15K | 0 | 17K | 30M | 14M | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||||||||
| Net Debt | -7.3M | -2.6M | -7.4M | -40M | -24M | -26M | 49M | 52M | 68M | 90M | -21M | -7.7M | 59M |
| Cash & Equiv. | 17M | 10M | 9.9M | 43M | 27M | 27M | 56M | 51M | 87M | 51M | 103M | 88M | 138M |
| Long-Term Debt | 15M | 14M | 1.8M | 2.8M | 2.8M | 0 | 100M | 95M | 143M | 131M | 72M | 69M | 194M |
| Debt/Equity | 2.42 | 17.35 | -1.77 | 0.07 | 0.14 | 0.01 | 1.19 | 0.73 | 1.02 | 1.05 | 0.24 | 0.17 | 0.50 |
| Interest Coverage | -12.5 | -8.4 | -7.7 | -12.0 | -10.9 | -4.6 | -5.4 | -4.5 | -2.0 | 0.9 | 10.0 | 26.9 | 29.7 |
| Equity | 6.0M | 821K | -4.5M | 40M | 20M | 26M | 88M | 141M | 152M | 135M | 349M | 477M | 390M |
| Total Assets | 27M | 24M | 24M | 108M | 89M | 127M | 208M | 276M | 348M | 329M | 489M | 624M | 665M |
| Total Liabilities | 21M | 23M | 28M | 68M | 69M | 101M | 119M | 135M | 196M | 194M | 140M | 147M | 275M |
| Intangibles | N/A | N/A | 0 | 4.8M | 4.0M | 3.2M | 2.4M | 1.7M | 1.0M | 499K | 460K | 632K | 630K |
| Retained Earnings | -69M | -87M | -107M | -151M | -216M | -265M | -340M | -412M | -478M | -506M | -309M | -162M | -116M |
| Working Capital | 20M | 17M | 10M | 53M | 35M | 72M | 134M | 178M | 231M | 207M | 276M | 397M | 438M |
| Current Assets | 24M | 21M | 22M | 62M | 45M | 86M | 154M | 209M | 270M | 257M | 331M | 467M | 511M |
| Current Liabilities | 4.2M | 4.2M | 11M | 9.4M | 9.6M | 14M | 20M | 30M | 39M | 50M | 56M | 70M | 74M |
| Per Share Data | |||||||||||||
| EPS | -0.45 | -0.43 | -0.40 | -0.96 | -1.45 | -0.89 | -0.88 | -0.51 | -0.33 | -0.13 | 0.81 | 0.60 | 0.70 |
| Owner EPS | -0.44 | -0.42 | -0.41 | -0.88 | -1.49 | -1.50 | -1.26 | -0.86 | -0.36 | -0.02 | 0.40 | 0.09 | 0.42 |
| Book Value | 0.16 | 0.02 | -0.09 | 0.88 | 0.44 | 0.48 | 1.03 | 1.00 | 0.76 | 0.62 | 1.43 | 1.95 | 1.68 |
| Cash Flow/Share | -0.40 | -0.37 | -0.38 | -0.81 | -1.38 | -1.40 | -1.19 | -0.80 | -0.30 | 0.04 | 0.49 | 0.21 | 0.75 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 37.2M | 41.5M | 48.5M | 45.8M | 45.3M | 54.2M | 86.1M | 140.5M | 199.7M | 217.2M | 244.0M | 244.9M | 232.3M |
| Valuation | |||||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 21.5 | 32.1 | 11.8 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 243.7 | 38.6 | 169.7 | 17.8 |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 46.7 | 29.7 | 24.1 | 9.2 |
| Price/Book | 17.2 | 106.4 | N/A | 3.5 | 5.1 | 18.3 | 4.6 | 1.2 | 4.8 | 7.3 | 12.2 | 9.9 | 4.9 |
| Price/Sales | N/A | N/A | 26.5 | 7.7 | N/A | 17.0 | 13.0 | 2.9 | 2.9 | 3.1 | 6.9 | 8.6 | 3.8 |
| FCF Yield | -16.5% | -17.7% | -8.4% | -28.0% | -64.1% | -16.7% | -28.3% | -74.7% | -10.0% | 0.4% | 2.6% | 0.6% | 5.6% |
| Market Cap | 103M | 87M | 218M | 143M | 101M | 479M | 406M | 169M | 735M | 982M | 4.3B | 4.7B | 1.9B |
| Avg. Price | 9.54 | 9.27 | 6.24 | 3.78 | 4.92 | 4.11 | 2.81 | 1.69 | 2.23 | 3.68 | 12.08 | 17.90 | 8.27 |
| Year-End Price | 11.10 | 8.41 | 4.80 | 3.08 | 2.23 | 3.95 | 2.07 | 1.20 | 3.68 | 4.52 | 17.45 | 19.28 | 8.27 |
ADMA BIOLOGICS, INC. passes 3 of 9 quality checks, indicating weak fundamentals.
ADMA BIOLOGICS, INC. trades at 13.8x trailing earnings, compared to its 15-year median P/E of 26.8x, suggesting it is currently Cheap relative to its historical range. On a free-cash-flow basis, the stock trades at 70.8x vs a median of 38.6x. The company's 5-year average ROIC is 7.0% with a gross margin of 33.5%. Total shareholder yield (buybacks) is 1.7%. At current prices, the estimated annualized return to fair value is +42.2%.
ADMA BIOLOGICS, INC. (ADMA) has a net profit margin of 28.8%. This is a strong margin indicating high profitability.
ADMA BIOLOGICS, INC. (ADMA) generated $28 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
ADMA BIOLOGICS, INC. (ADMA) has a debt-to-equity ratio of 0.17. This indicates a conservatively financed balance sheet.
ADMA BIOLOGICS, INC. (ADMA) reported earnings per share (EPS) of $0.60 in its most recent fiscal year.
ADMA BIOLOGICS, INC. (ADMA) has a return on equity (ROE) of 35.6%. This indicates the company generates strong returns for shareholders.
ADMA BIOLOGICS, INC. (ADMA) has a 5-year average gross margin of 33.5%. This indicates decent pricing power.
The Ledger Terminal provides 15 years of financial data for ADMA BIOLOGICS, INC. (ADMA), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
ADMA BIOLOGICS, INC. (ADMA) has a book value per share of $1.95, based on its most recent annual SEC filing.